![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/research/pfizer-bms-and-more-take-part-fnih-parkinsons-biomarker-project
https://pharmaphorum.com/news/first-rare-disease-therapies-chosen-fda-start-programme
https://www.fiercebiotech.com/research/fda-selects-denali-neurogene-larimar-and-grace-sciences-rare-disease-therapy-pilot
https://www.globenewswire.com/news-release/2024/06/03/2892216/0/en/Denali-Therapeutics-Announces-FDA-Has-Selected-DNL126-ETV-SGSH-for-MPS-IIIA-Sanfilippo-Syndrome-Type-A-for-START-Pilot-Program-Intended-to-Accelerate-Development-of-Rare-Disease-Th.html
https://www.globenewswire.com/news-release/2024/05/07/2877179/0/en/Denali-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/05/01/2873193/0/en/Denali-Therapeutics-Announces-Completion-of-Enrollment-for-Regimen-G-Evaluating-eIF2B-Agonist-DNL343-in-the-Phase-2-3-HEALEY-ALS-Platform-Trial.html
https://www.globenewswire.com//news-release/2024/02/27/2836005/0/en/Denali-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com//news-release/2024/02/27/2835991/0/en/Denali-Therapeutics-Announces-500-million-Private-Placement-Equity-Financing.html
https://www.fiercebiotech.com/biotech/tail-sanofi-partnered-als-flop-denali-confirms-layoffs
https://www.reuters.com/business/healthcare-pharmaceuticals/denali-sanofis-als-drug-fails-meet-main-goal-mid-stage-trial-2024-02-16/